TREM1 and metabolic dysfunction-associated steatohepatitis: Our results demonstrated that there was a remarkable increase in TREM-1 at both the mRNA and protein levels in livers from NASH as compared with those in livers from NCD-fed controls; however, myricetin-treated NASH mice decreased the TREM-1 expression both in gene and protein levels when compared with vehicle-treated NASH mice (Figures 7C,D).